Withycombe Janice S, Post-White Janice E, Meza Jane L, Hawks Ria G, Smith Lynette M, Sacks Nancy, Seibel Nita L
Children's Cancer and Blood Disorder Center, South Carolina Cancer Center, Columbia, South Carolina, USA.
Pediatr Blood Cancer. 2009 Dec 15;53(7):1249-54. doi: 10.1002/pbc.22237.
This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.
Patients (1,638) were enrolled in CCG 1961 from November 1996 to May 2002. Weight was measured as BMI percent (%), specific for age and gender, and defined as 100 x ln(BMI/median BMI).
By the end of treatment, 23% of children were obese (BMI >or=95%), compared with 14% at diagnosis. Children who received post-induction intensified therapy (arms C, D, SER with Doxorubicin or Idarubicin) had higher gastrointestinal toxicities and lower BMI% from consolidation through interim maintenance 1. BMI% then increased for all arms between delayed intensification and maintenance 1 or 2. Children who were of Black or Hispanic race, obese at diagnosis, or who had grade 3 or 4 pancreatitis/glucose toxicities during induction had higher BMI% throughout treatment. Children were more likely to be obese at the end of the study if they were aged 5-9 years at diagnosis or female gender. Cranial radiation was not a predictor of obesity.
Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation. The beginning of maintenance therapy may be the best time to intervene with nutritional and behavioral interventions, particularly for children who are obese or aged 5-9 years at diagnosis, female, Black or Hispanic, or those with metabolic toxicities during induction.
这项回顾性分析定义并描述了在儿童癌症组CCG 1961方案下接受治疗的具有高危特征的急性淋巴细胞白血病(ALL)患儿在治疗期间体重变化的模式和预测因素。
1996年11月至2002年5月期间,1638例患者被纳入CCG 1961研究。体重以BMI百分比(%)衡量,根据年龄和性别而定,定义为100×ln(BMI/中位BMI)。
治疗结束时,23%的儿童肥胖(BMI≥95%),而诊断时为14%。接受诱导后强化治疗(C、D、含阿霉素或伊达比星的SER组)的儿童胃肠道毒性较高,从巩固期到中期维持期1的BMI%较低。然后,在延迟强化期和维持期1或2之间,所有组的BMI%均有所增加。黑人或西班牙裔种族、诊断时肥胖或诱导期出现3级或4级胰腺炎/葡萄糖毒性的儿童在整个治疗过程中BMI%较高。如果儿童在诊断时年龄为5 - 9岁或为女性,则在研究结束时更有可能肥胖。颅脑放疗不是肥胖的预测因素。
高危儿童ALL的成功治疗与肥胖有关,与颅脑放疗无关。维持治疗开始时可能是进行营养和行为干预的最佳时机,特别是对于诊断时肥胖或年龄为5 - 9岁、女性、黑人或西班牙裔、或诱导期有代谢毒性的儿童。